Slide 1: FY25 Results
_ March 4th 2026 FY25 RESULTS Fa.
Slide 2: Disclaimer
Disclaimer IMPORTANT NOTICE This presentations is being furnished to you solely for your information and may not be reproduced or redistributed to any other person. This presentation might contain certain forward-looking statements that reflect the Company’s management current views with respect to
Slide 3: Agenda
Agenda FY25 Executive FY25 Financials Outlook & Guidance Summary
Slide 4: FY25 Executive Summary
FY25 Executive Summary Net Sales Gross Profit Adj. EBITDA €1,047.2m €219.4m €156m +0.3% c. FX vs. FY24 -1.7% rep. FX vs. FY24 +151Bps +8.8% or +€12.6m vs. FY24 +€12.4m vs. FY24 19.2% on Value Added Sales (+165Bps) Value Added Sales +1.5% c.FX vs. FY24 Net Debt Dividends & Buyback Adj. Net Income Div
Slide 5: FY25 Executive Summary
FY25 Executive Summary FY25 Net sales have been impacted by lower pack sold to clients (-€8.8m @ c.FX) and adverse Fx fluctuations (-€21.1m almost entirely driven by EURO appreciation vs. USD, CNY and KRW). Excluding those factors, sales on a like-for-like basis would have increased by +€12.2m. FY25
Slide 6: Executive Summary – FY25 & 4Q25 main KPIs
FY25 Executive Summary – FY25 & 4Q25 main kpi’s €m FY25 FY24 % vs FY24 Rep FX c FX Revenues 1047.2 1064.9 (1.7%) 0.3% FY Group record in terms of EBITDA Value Added Sales 812.8 817.1 (0.5%) 1.5% and Net Income despite adverse FX Adj. EBITDA 156.0 143.3 8.8% fluctuations. Adj. EBITDA % 14.9% 13.5% 14
Slide 7: 4Q25 and FY25 Revenues by BU's
FY25 Financials – 4Q25 and FY25 Revenues by BU’s 4Q25 FY25 FY24 Hair & Body Hair & Body Hair & Body 23,6% 22,1% 26,1% 15,2% 61,2% 15,4% 58,2% 62,6% Make Up Skincare Make Up Skincare Make Up 15,7% Skincare • Make-up generated revenues of €655.2m, marking another year of solid growth (+5.7%). It was t
Slide 8: 4Q25 and FY25 Revenues by Region
FY25 Financials – 4Q25 and FY25 Revenues by Region 4Q25 FY25 FY24 Asia Asia Asia 21,6% 21,5% 19,9% 50,4% EMEA 50,8% EMEA 52,5% EMEA 28,0% 27,7% 27,6% Americas Americas Americas • EMEA reported revenues of €531.7m, down -5.0% vs. FY24. Sales recorded solid growth in €m FY25 FY24 % vs FY24 both the Ma
Slide 9: 4Q25 and FY25 Revenues by Customer Type
FY25 Financials – 4Q25 and FY25 Revenues by Customer Type 4Q25 FY25 FY24 Retailers Retailers Retailers 7,2% 6,8% 6,5% 45,2% Multinationals 44,0% Multinationals 48,8% Multinationals 47,6% 44,5% Emerging Brands 49,4% Emerging Brands Emerging Brands €m FY25 FY24 % vs FY24 • Multinationals generated rev
Slide 10: Results overview
FY25 Financials – Results overview • FY25 Net Sales amounted to €1,047.2m, up 0.3% YoY at c.FX, and slightly down (-1.7%) on a reported basis, due to the significant appreciation of the Euro against the Korean Var. vs % vs Won, the US Dollar and the Chinese Renminbi. A meaningful improvement in the
Slide 11: Adjusted EBITDA by BU
FY25 Financials – Adjusted EBITDA by BU €m Group Adj. EBITDA Make-up Skincare Hair&Body +9% EBITDA/Net 156,0 Sales 143,3 +29% EBITDA/Value Added Sales 107,0 +7% -37% 83,1 34,9 25,3 27,0 17.5% 19.2% 21,9 13.4% 16.3% 15.2% 16.8% 12.6% 13.5% 14.9% 9.5% FY24 FY25 FY24 FY25 FY24 FY25 FY24 FY25 • Make-up
Slide 12: Cash Flow and Net Debt
FY25 Financials – Cash Flow and Net Debt Var. vs • Operating cash flow in FY25 amounted to €73.5m, representing a strong increase vs. LY €m FY25 FY24 (+€16.4m), despite capital expenditure as a percentage of net sales reflected the Group’s one- FY24 off expansion plans, with total investments reachi
Slide 13: Outlook & Guidance
Outlook & Guidance Our view on We enter 2026 with confidence. After a 2025 marked by weakness in Western markets, particularly the US, and a clear recovery the in Asia, especially China in the second half, we expect a gradual recovery of the US market in 2026. This represents a reversal compared to
Slide 14: Appendix
Slide 15: P&L and Related Adjustments
P&L and Related Adjustments €m FY25 FY24 Var. vs FY24 % vs FY24 Net Sales 1047.2 1,064.9 (17.7) (1.7%) COGS (827.8) (857.9) 30.1 (3.5%) Industrial gross profit 219.4 207.0 12.4 6.0% % on net sales 21.0% 19.4% Research & Development and innovation costs (41.0) (40.4) (0.6) 1.5% Selling expenses (25.9
Slide 16: Balance Sheet and Cash Flow
Balance Sheet and Cash Flow Var. vs €m 31Dec25 31Dec24 31Dec24 Tangible Assets 252.1 248.5 3.6 Intangible Assets 72.1 63.2 8.8 Goodwill 133.8 133.7 0.1 Investments 1.5 1.5 0.0 Deferred tax assets 26.1 29.3 (3.2) Other non-current Assets/Liab. (10.0) (11.8) 1.8 Non-current Assets 475.7 464.5 11.2 Inv
Slide 17: Definitions
Definitions For the purpose of providing information in line with the performance analysis and control parameters of the Group, non-IFRS alternative performance measures are used by management to provide information for a better assessment of the results of operations and the financial position of t